Radiolabeled bevacizumab as a tracer of VEGF expression in patients with colorectal liver metastases

Radiolabeled bevacizumab as a tracer of VEGF expression in patients with colorectal liver metastases - Avastin-scanning in patients with colorectal liver metastases

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON29757

Enrollment

Registered

2006-05-04

Start date

2006-05-01

Completion date

Unknown

Last updated

2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal liver metastases

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Colorectal liver metastases, planned surgical resection within 6 weeks.

Exclusion criteria

Exclusion criteria: Pregnancy, lactation, recent chemotherapy (within 3 months after last chemotherapy regimen).

Design outcomes

Primary

Measure	Time frame
Correlation of In-111 labeled bevacizumab and histological VEGF expression.	—

Secondary

Measure	Time frame
Not applicable.	—

Countries

Netherlands

Outcome results